A Clinical Trial to Explore the Efficacy of Two Investigational Products on Post-Exercise Hydration in Recreationally Active Healthy Adults

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorChobani

About this trial

The goal of this clinical trial is to explore the efficacy of two investigational products for promoting post-exercise hydration in recreationally active healthy adults. The main question it aims to answer is: Does consumption of each investigational product (IP) beverage, compared to control beverages, result in differences in blood hematocrit and serum osmolality at 0.5, 2, 4, and 8 hours post-exercise in recreationally active healthy adults? Researchers will compare two IPs to control beverages to see if the IPs are effective for supporting post-exercise hydration. Participants will be required to consume the IPs, as well as control beverages. Participants will also complete questionnaires, undergo an exercise challenge, and record their food and beverage intake.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Males and females between 18 and 65 years of age

Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,

Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)

Double-barrier method

Disqualifiers

Individuals who are pregnant, breast feeding, or planning to become pregnant during the study

Allergy, sensitivity, intolerance, or dietary restriction, including dairy sensitivity/intolerance, preventing consumption of investigational product, comparator/control ingredients, or standardized meal

Self-reported unstable weight for the past 3 months defined as having gained or lost more than 5% of body weight prior to baseline

Poor venous access as assessed by the QI

Trial design

Design model

Crossover

Treatments tested in this trial

  • Potassium15

    Dietary supplement

    Immediately after exercise, participants will consume one bottle (591 mL) of the study product within 10 minutes and in the presence of clinic staff.

  • Potassium10

    Dietary supplement

    Immediately after exercise, participants will consume one bottle (591 mL) of the study product within 10 minutes and in the presence of clinic staff.

  • Plain Water

    Other intervention

    Immediately after exercise, participants will consume one bottle (591 mL) of the study product within 10 minutes and in the presence of clinic staff.

  • Gatorade Fruit Punch

    Other intervention

    Immediately after exercise, participants will consume one bottle (591 mL) of the study product within 10 minutes and in the presence of clinic staff.

Treatment groups

32 Participants
are divided into 4 treatment groups
Group A: Potassium15Experimental treatment 1 intervention
Group B: Potassium10Experimental treatment 1 intervention
Group C: WaterPlacebo comparator 1 intervention
Group D: Marketed sports beverageActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in Blood Hematocrit

Change in blood hematocrit (L/L) 0.5-, 2-, 4-, and 8-hours post-exercise between each IP beverage and control beverages

Time frame
0.5-, 2-, 4-, and 8-hours post-exercise from visit 2 to visit 5
2

Change in Serum Osmolality

Change in serum osmolality (mOsm/kg) 0.5-, 2-, 4-, and 8-hours post-exercise between each IP beverage and control beverages

Time frame
0.5-, 2-, 4-, and 8-hours post-exercise from visit 2 to visit 5

Secondary outcomes

1

Change in Mean Corpuscular Volume

Change in mean corpuscular volume (MCV, fL) at 0.5-, 2-, 4-, and 8-hours post-exercise following ingestion of each IP beverage compared with control beverages (Visits 2-5)

Time frame
0.5-, 2-, 4-, and 8-hours post-exercise from visit 2 to visit 5
2

Change in Sodium

Change in serum sodium concentration (mmol/L) at 0.5-, 2-, 4-, and 8-hours post-exercise following ingestion of each IP beverage compared with control beverages (Visits 2-5).

Time frame
0.5-, 2-, 4-, and 8-hours post-exercise from visit 2 to visit 5
3

Change in Potassium

Change in serum potassium concentration (mmol/L) at 0.5-, 2-, 4-, and 8-hours post-exercise following ingestion of each IP beverage compared with control beverages (Visits 2-5).

Time frame
0.5-, 2-, 4-, and 8-hours post-exercise from visit 2 to visit 5
4

Change in Blood Urea Nitrogen

Change in blood urea nitrogen (mg/dL) at 0.5-, 2-, 4-, and 8-hours post-exercise following ingestion of each IP beverage compared with control beverages (Visits 2-5).

Time frame
0.5-, 2-, 4-, and 8-hours post-exercise from visit 2 to visit 5

Other outcomes

1

Incidence of post-emergent adverse events (AE)

Incidence of post-emergent adverse events (AE)

Time frame
From screening (Day -45 to Day -7) through final study visit (Visit 5)
2

Clinically relevant changes in vital signs (blood pressure (systolic and diastolic)) and heart rate after supplementation

Change in systolic blood pressure (mmHg), diastolic blood pressure (mmHg), and heart rate (beats per minute) from screening through final study visit following supplementation.

Time frame
From screening (Day -45 to Day -7) through final study visit (Visit 5)

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chobani

Lead sponsor

KGK Science Inc.

Collaborator

This trial is not recruiting at the moment. You can still explore other options: